Prosecution Insights
Last updated: August 18, 2026

Examiner: BELYAVSKYI, MICHAIL A

Tech Center 1600 • Art Units: 1641 1643 1644 1646 1647 1653 1654

This examiner grants 64% of resolved cases

Performance Statistics

64.1%
Allow Rate
+4.1% vs TC avg
1,181
Total Applications
+27.7%
Interview Lift
1148
Avg Prosecution Days
Based on 1110 resolved cases, 2023–2026

Rejection Statute Breakdown

3.6%
§101 Eligibility
14.7%
§102 Novelty
31.4%
§103 Obviousness
19.6%
§112 Clarity

Currently Pending Office Actions

App #TitleStatusAssignee
18020611 TARGETED PROTEIN DEGRADATION IN THERAPEUTIC CELLS Final Rejection The Regents of the University of California
17863149 METHODS FOR TREATING VIRAL INFECTIONS Non-Final OA The Regents of The University of California
18691410 METHODS OF AMPLIFYING TUMOR-REACTIVE IMMUNE POPULATIONS USING ORGANOIDS Non-Final OA The Board of Trustees of the Leland Stanford Junior University
17793024 PERICYTE-SPARING THERAPY Non-Final OA The Board of Trustees of the Leland Stanford Junior University
18044482 ENGINEERED IMMUNE CELLS FOR REAGENT DELIVERY Non-Final OA REGENTS OF THE UNIVERSITY OF MINNESOTA
17765043 ELUTION OF MONOCLONAL ANTIBODIES IN PROTEIN A AFFINITY CHROMATOGRAPHY Non-Final OA Merck Patent GmbH
17800387 CAR T CELLS TARGETING THE INTEGRIN ALPHAV BETA3 EXHIBIT ROBUST ANTI-TUMOR RESPONSES AGAINST GLIOMAS AND OTHER SOLID TUMOR MALIGNANCIES Final Rejection University of Virginia Patent Foundation
17923029 METHODS FOR TREATING OR REDUCING THE SEVERITY OF A VIRAL INFECTION Non-Final OA Washington University
17904706 Bispecific GD2 and B7H3 Binding Molecules and Methods of Use Non-Final OA WISCONSIN ALUMNI RESEARCH FOUNDATION
16547907 EXPANSION OF HPSC-DERIVED GRANULOCYTIC AND LYMPHOID PROGENITORS WITH UM171 Final Rejection Wisconsin Alumni Research Foundation
18059369 MODIFIED HEMATOPOIETIC STEM/PROGENITOR AND NON-T EFFECTOR CELLS, AND USES THEREOF Final Rejection Seattle Children's Hospital d/b/a Seattle Children's Research Institute
18277367 TRUNCATED DOMAIN IV EGFR AND USES THEREOF Final Rejection CITY OF HOPE
17789930 METHODS OF MAKING AND USING REGULATORY T CELLS AND EFFECTOR T CELLS HAVING CHIMERIC ANTIGEN RECEPTORS TARGETED TO CD6, CD19, AND/OR AN IL-13R FOR TREATMENT OF AUTOIMMUNE DISORDERS AND CANCERS Non-Final OA CITY OF HOPE
18424298 BIOMARKERS AND METHODS FOR MEASURING AND MONITORING JUVENILE IDIOPATHIC ARTHRITIS ACTIVITY Non-Final OA Laboratory Corporation of America Holdings

Facing This Examiner?

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.

Build Your Strategy

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month